Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
International Journal of Tuberculosis and Lung Disease, Volume 12, No. 2, Year 2008
Notification
URL copied to clipboard!
Description
SETTING: Current treatment for pulmonary tuberculosis (TB) might be shortened by the incorporation of fluoroquinolones (FQs). OBJECTIVES: A Phase II study aimed to assess the sterilising activities of three novel regimens containing FQs before a Phase III trial of a 4-month regimen containing gatifloxacin (GFX). DESIGN: A total of 217 newly diagnosed smear-positive patients were randomly allocated to one of four regimens: isoniazid (INH), pyrazinamide and rifampicin (RMP) with either ethambutol, GFX, moxifloxacin (MFX) or ofloxacin (OFX) for 2 months. At the end of the study, RMP and INH were given for 4 months. The rates of elimination of Mycobacterium tuberculosis were compared in the regimens using non-linear mixed effects modelling of the serial sputum colony counts (SSCC) during the first 8 weeks. RESULTS: After adjustment for covariates, MFX substitution appeared superior during the early phase of a biexponential fall in colony counts, but significant and similar acceleration of bacillary elimination during the late phase occurred with both GFX and MFX (P = 0.002). Substitution of OFX had no effect. These findings were supported by estimates of time to conversion, using Cox regression, but there were no significant differences in proportions culture-negative at 8 weeks. CONCLUSIONS: GFX and MFX improve the sterilising activity of regimens and might shorten treatment; their progression into Phase III trials therefore seems warranted. © 2008 The Union.
Authors & Co-Authors
Rustomjee, Roxana
South Africa, Tygerberg
South African Medical Research Council
Lienhardt, Christian
France, Marseille
Ird Institut de Recherche Pour le Developpement
France, Paris
International Union Against Tuberculosis and Lung Disease
Kanyok, Thomas P.
Switzerland, Geneva
Organisation Mondiale de la Santé
Davies, Geraint Rhys
United Kingdom, Liverpool
University of Liverpool
Levin, Jonathan B.
South Africa, Tygerberg
South African Medical Research Council
Mthiyane, Thuli C.P.
South Africa, Tygerberg
South African Medical Research Council
Reddy, Carl
South Africa, Tygerberg
South African Medical Research Council
Sturm, Adriaan Willem
South Africa, Durban
The Nelson R. Mandela Medical School
Sirgel, Frederick Adriaan
South Africa, Stellenbosch
Stellenbosch University
Allen, Jenny
South Africa, Tygerberg
South African Medical Research Council
Coleman, David J.
United Kingdom, London
St George’s, University of London
Fourie, P. B.
South Africa, Tygerberg
South African Medical Research Council
Mitchison, Dennis Anthony
United Kingdom, London
St George’s, University of London
Bah Sow, Oumou
Unknown Affiliation
Diop, H.
Unknown Affiliation
Fielding, Katherine Linda
Unknown Affiliation
Gninafon, Martin
Unknown Affiliation
Mitchison, Denny A.
Unknown Affiliation
Lienhardt, C.
Unknown Affiliation
Odhiambo, Joseph A.
Unknown Affiliation
Perronne, Christian M.
Unknown Affiliation
Portaels, Françoise Ç.Oise
Unknown Affiliation
Ramjee, A.
Unknown Affiliation
Master, Iqbal M.
Unknown Affiliation
Olowolagba, Ayo
Unknown Affiliation
Chinappa, Thilgavathy
Unknown Affiliation
Osburne, G.
Unknown Affiliation
Bamber, Sheila A.
Unknown Affiliation
Pala, Alessandra S.
Unknown Affiliation
Pillay, L.
Unknown Affiliation
Tembe, C.
Unknown Affiliation
Mpangase, Primrose
Unknown Affiliation
Hadebe, T.
Unknown Affiliation
Ngcobo, C. P.
Unknown Affiliation
Mkhize, Z.
Unknown Affiliation
Dlamini, C.
Unknown Affiliation
Gill, L.
Unknown Affiliation
Dube, T.
Unknown Affiliation
Saul, M.
Unknown Affiliation
Merle, C. S.
Unknown Affiliation
Suma, K. F.
Unknown Affiliation
Statistics
Citations: 41
Authors: 41
Affiliations: 8
Identifiers
ISSN:
10273719
Research Areas
Infectious Diseases